RhumbLine Advisers
LXEO icon

RhumbLine Advisers’s Lexeo Therapeutics LXEO Stock Holding History

RhumbLine Advisers’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$414K Buy
72,082
+2,713
+4% +$19.2K ﹤0.01% 2725
2025
Q4 		$689K Buy
69,369
+37,605
+118% +$343K ﹤0.01% 2453
2025
Q3 		$211K Sell
31,764
-226
-0.7% -$1.09K ﹤0.01% 3193
2025
Q2 		$129K Buy
31,990
+1,798
+6% +$5.91K ﹤0.01% 3441
2025
Q1 		$105K Buy
30,192
+4,995
+20% +$22.1K ﹤0.01% 3375
2024
Q4 		$166K Buy
25,197
+4,127
+20% +$32.5K ﹤0.01% 3293
2024
Q3 		$190K Buy
21,070
+7,713
+58% +$92K ﹤0.01% 3264
2024
Q2 		$214K Buy
13,357
+3,627
+37% +$52.7K ﹤0.01% 3192
2024
Q1 		$153K Buy
+9,730
New +$152K ﹤0.01% 3294

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return